NEW YORK, April 25, 2017 /PRNewswire/ -- The federal litigation established in the U.S. District Court, Eastern District of Louisiana for lawsuits involving Taxotere and permanent alopecia continues to grow. A new update provided by the U.S. Judicial Panel on Multidistrict Litigation (JPML) shows that 949 Taxotere lawsuits were pending in the proceeding as of April 17, 2017, indicating that 150 cases have either been filed in or transferred to the multidistrict litigation since the Panel issued its previous report in March. (In Re: Taxotere (Docetaxal) Products Liability Litigation - MDL No. 2740)
"Our Firm continues to receive inquiries from Taxotere patients whose hair loss allegedly persisted long after their chemotherapy treatment ended. Based on our experience, it is not at all surprising that the federal litigation continues to grow at such a rapid pace," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm is now offering free case reviews to breast cancer patients and others whose hair failed to grow back following chemotherapy with Taxotere.
The Taxotere Litigation
The Taxotere litigation was established last October so that all federally-filed cases involving the drug's alleged potential to cause permanent alopecia could undergo coordinated pretrial proceedings. Initially, only 33 Taxotere lawsuits were transferred to the Eastern District of Louisiana.
Taxotere (docetaxel) is marketed by Sanofi-Aventis, and was initially approved by the U.S. Food & Drug Administration (FDA) in 1996 to treat breast cancer. Its approved indications have since grown to include head and neck cancer, gastric cancer, prostate cancer and non-small cell lung cancer. While Taxotere has been in wide use for more than two decades, it wasn't until December 2015 that its U.S. label was updated to note that cases of permanent alopecia had been reported among patients treated with the medication.
Hair loss is among the most common side effects of chemotherapy. However, Taxotere lawsuit plaintiffs claim that the drug is more likely to result in permanent alopecia compared to equally effective alternative chemotherapy agents. They also question why Sanofi-Aventis has long advised physicians, patients, and regulatory agencies in the European Union and Canada that treatment with Taxotere may increase a patient's risk of permanent hair loss, while the U.S. labeling merely stated that "hair generally grows back" following treatment.
Taxotere cancer patients who allegedly experienced permanent alopecia following chemotherapy with this medication may be eligible to join this litigation. To learn more about filing a Taxotere lawsuit, please visit Bernstein Liebhard LLP's website, or call 800-511-5092 to arrange for a free, no obligation case review.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092
ATTORNEY ADVERTISING. © 2017 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com
http://www.rxinjuryhelp.com/
https://plus.google.com/115936073311125306742?rel=author
SOURCE Bernstein Liebhard LLP
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article